Sheybani Arsham, Scott Rachel, Samuelson Thomas W, Kahook Malik Y, Bettis Daniel I, Ahmed Iqbal Ike K, Stephens J David, Kent Delaney, Ferguson Tanner J, Herndon Leon W
Washington University School of Medicine, St. Louis, MO, USA.
Baylor College of Medicine, Houston, TX, USA.
Ophthalmol Ther. 2020 Mar;9(1):1-14. doi: 10.1007/s40123-019-00222-z. Epub 2019 Nov 15.
Glaucoma is a chronic, debilitating disease and a leading cause of global blindness. Despite treatment efforts, 10% of patients demonstrate loss of vision. In the US, > 80% of glaucoma cases are classified as open-angle glaucoma (OAG), with primary open-angle (POAG) being the most common. Although there has been tremendous innovation in the surgical treatment of glaucoma as of late, two clinical variants of OAG, normal-tension glaucoma (NTG) and severe POAG, are especially challenging for providers because patients with access to care and excellent treatment options may progress despite achieving a "target" intraocular pressure value. Additionally, recent research has highlighted the importance of nocturnal IOP control in avoiding glaucomatous disease progression. There remains an unmet need for new treatment options that can effectively treat NTG and severe POAG patients, irrespective of baseline IOP, while overcoming adherence limitations of current pharmacotherapies, demonstrating a robust safety profile, and more effectively controlling nocturnal IOP.Funding The Rapid Service Fees were funded by the corresponding author, Tanner J. Ferguson, MD.
青光眼是一种慢性致残性疾病，也是全球失明的主要原因。尽管进行了治疗，但仍有10%的患者视力丧失。在美国，超过80%的青光眼病例被归类为开角型青光眼（OAG），其中原发性开角型青光眼（POAG）最为常见。尽管近年来青光眼的手术治疗有了巨大创新，但OAG的两种临床变体，即正常眼压性青光眼（NTG）和重度POAG，对医疗服务提供者来说尤其具有挑战性，因为即便获得了医疗服务并采用了优质的治疗方案，患者的眼压达到了“目标”值，病情仍可能进展。此外，最近的研究强调了控制夜间眼压对避免青光眼病情进展的重要性。目前仍迫切需要新的治疗方案，这些方案能够有效治疗NTG和重度POAG患者，无论其基线眼压如何，同时克服当前药物治疗的依从性限制，展现出强大的安全性，并更有效地控制夜间眼压。资金来源快速服务费由通讯作者坦纳·J·弗格森医学博士提供。
